Banco Santander S.A. Purchases Shares of 4,911 Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Banco Santander S.A. purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 1st quarter, Holdings Channel.com reports. The institutional investor purchased 4,911 shares of the medical equipment provider’s stock, valued at approximately $648,000.

Several other institutional investors also recently modified their holdings of the stock. PFG Advisors raised its stake in Zimmer Biomet by 4.6% during the 4th quarter. PFG Advisors now owns 1,899 shares of the medical equipment provider’s stock valued at $231,000 after purchasing an additional 84 shares during the period. Quent Capital LLC raised its stake in Zimmer Biomet by 21.6% during the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock valued at $63,000 after purchasing an additional 92 shares during the period. Chicago Partners Investment Group LLC raised its stake in Zimmer Biomet by 3.3% during the 4th quarter. Chicago Partners Investment Group LLC now owns 2,894 shares of the medical equipment provider’s stock valued at $349,000 after purchasing an additional 92 shares during the period. North Star Investment Management Corp. raised its stake in Zimmer Biomet by 16.6% during the 1st quarter. North Star Investment Management Corp. now owns 669 shares of the medical equipment provider’s stock valued at $88,000 after purchasing an additional 95 shares during the period. Finally, First Bancorp Inc ME raised its stake in Zimmer Biomet by 5.3% during the 1st quarter. First Bancorp Inc ME now owns 1,970 shares of the medical equipment provider’s stock valued at $260,000 after purchasing an additional 100 shares during the period. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

NYSE ZBH traded down $0.89 during trading on Friday, reaching $110.50. 1,510,715 shares of the company traded hands, compared to its average volume of 1,652,033. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.80 and a current ratio of 1.66. The stock’s 50 day moving average price is $111.42 and its two-hundred day moving average price is $119.89. The company has a market cap of $22.73 billion, a price-to-earnings ratio of 23.92, a P/E/G ratio of 1.99 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a 1-year low of $102.00 and a 1-year high of $143.24.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, topping the consensus estimate of $1.87 by $0.07. The business had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. Zimmer Biomet’s revenue was up 3.2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.89 EPS. As a group, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Wednesday, June 26th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.87%. The ex-dividend date is Wednesday, June 26th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on ZBH shares. Barclays lowered their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating on the stock in a report on Friday, May 31st. Argus upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a report on Tuesday, May 21st. Truist Financial lowered their price target on shares of Zimmer Biomet from $130.00 to $117.00 and set a “hold” rating on the stock in a report on Tuesday, July 16th. Citigroup lowered their price target on shares of Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Thursday, May 30th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $129.53.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.